ANAB
Price
$20.14
Change
+$0.17 (+0.85%)
Updated
Aug 15 closing price
Capitalization
563.38M
87 days until earnings call
NERV
Price
$2.25
Change
+$0.46 (+25.70%)
Updated
Aug 15 closing price
Capitalization
15.74M
86 days until earnings call
Interact to see
Advertisement

ANAB vs NERV

Header iconANAB vs NERV Comparison
Open Charts ANAB vs NERVBanner chart's image
AnaptysBio
Price$20.14
Change+$0.17 (+0.85%)
Volume$547.62K
Capitalization563.38M
Minerva Neurosciences
Price$2.25
Change+$0.46 (+25.70%)
Volume$422.87K
Capitalization15.74M
ANAB vs NERV Comparison Chart in %
Loading...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANAB vs. NERV commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Hold and NERV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (ANAB: $20.14 vs. NERV: $2.25)
Brand notoriety: ANAB and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 87% vs. NERV: 1841%
Market capitalization -- ANAB: $563.38M vs. NERV: $15.74M
ANAB [@Biotechnology] is valued at $563.38M. NERV’s [@Biotechnology] market capitalization is $15.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • ANAB’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than ANAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 5 TA indicator(s) are bullish while NERV’s TA Score has 6 bullish TA indicator(s).

  • ANAB’s TA Score: 5 bullish, 5 bearish.
  • NERV’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NERV is a better buy in the short-term than ANAB.

Price Growth

ANAB (@Biotechnology) experienced а -4.23% price change this week, while NERV (@Biotechnology) price change was +27.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

ANAB is expected to report earnings on Nov 11, 2025.

NERV is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($563M) has a higher market cap than NERV($15.7M). ANAB YTD gains are higher at: 52.115 vs. NERV (1.278). NERV has higher annual earnings (EBITDA): 8.58M vs. ANAB (-76.35M). ANAB has more cash in the bank: 340M vs. NERV (17.3M). NERV has less debt than ANAB: NERV (0) vs ANAB (15.6M). ANAB has higher revenues than NERV: ANAB (112M) vs NERV (0).
ANABNERVANAB / NERV
Capitalization563M15.7M3,586%
EBITDA-76.35M8.58M-890%
Gain YTD52.1151.2784,077%
P/E RatioN/A2.19-
Revenue112M0-
Total Cash340M17.3M1,965%
Total Debt15.6M0-
FUNDAMENTALS RATINGS
ANAB vs NERV: Fundamental Ratings
ANAB
NERV
OUTLOOK RATING
1..100
5886
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8559
P/E GROWTH RATING
1..100
7699
SEASONALITY SCORE
1..100
n/a44

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (38) in the Biotechnology industry is somewhat better than the same rating for ANAB (85). This means that NERV’s stock grew somewhat faster than ANAB’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ANAB (100). This means that NERV’s stock grew similarly to ANAB’s over the last 12 months.

NERV's SMR Rating (100) in the Biotechnology industry is in the same range as ANAB (100). This means that NERV’s stock grew similarly to ANAB’s over the last 12 months.

NERV's Price Growth Rating (59) in the Biotechnology industry is in the same range as ANAB (85). This means that NERV’s stock grew similarly to ANAB’s over the last 12 months.

ANAB's P/E Growth Rating (76) in the Biotechnology industry is in the same range as NERV (99). This means that ANAB’s stock grew similarly to NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABNERV
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 24 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
82%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARTIX35.600.15
+0.42%
Artisan International Investor
RISIX14.53N/A
N/A
RBC International Small Cap Equity I
LKEQX40.40N/A
N/A
LKCM Equity
JDSCX33.05N/A
N/A
JPMorgan Small Cap Blend I
IMCVX9.74N/A
N/A
Voya Multi-Manager Mid Cap Value I

ANAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with CLRB. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
+0.85%
CLRB - ANAB
39%
Loosely correlated
-1.81%
QTTB - ANAB
39%
Loosely correlated
+4.79%
AMRN - ANAB
38%
Loosely correlated
+4.06%
ADCT - ANAB
37%
Loosely correlated
-1.88%
HRMY - ANAB
35%
Loosely correlated
+0.99%
More